EFFECTIVENESS AND SAFETY OF CYD-TDV VACCINE IN CHILDREN
DOI:
https://doi.org/10.31004/jkt.v4i3.17156Keywords:
CYD-TDV Vaccine, Dengue Disease, Dengue VirusAbstract
Dengue virus is classified as an arbovirus and its incidence rate continues to grow, especially in children in the last few years recorded by WHO. In the absence of specific therapy to treat dengue, prevention with vaccination is the right choice, especially for Asia and endemic regions such as Indonesia. Until now, the vaccine for dengue is only available in one commercial formulation (CYD-TDV) which has been licensed and developed by Sanofi Pasteur. The purpose of this study is to determine the effectiveness and safety of the CYD-TDV vaccine for children in endemic areas. The method used in this study is a literature search. Conducted meta-analyses and systematic reviews published between 2017 and 2020 identified in MEDLINE, especially in children based on inclusion and exclusion criteria. The findings obtained are Immunogenicity in the test group vaccinated with CYD-TDV was higher than the control group and side effects between two groups were not significant. So it can be concluded CYD-TDV vaccine is effective and safe for children’s in endemic areas. This conclusion is the basis for further vaccine development, especially for Asian regions, such as Indonesia.References
Agarwal, R., Wahid, M. H., Yausep, O. E., Angel, S. H., & Lokeswara, A. W. (2017). The immunogenicity and safety of CYD-tetravalent dengue vaccine (CYD-TDV) in children and adolescents: a systematic review. Acta Med Indones, 49(1), 24–33.
Bhatt, S., Gething, P. W., Brady, O. J., Messina, J. P., Farlow, A. W., Moyes, C. L., Drake, J. M., Brownstein, J. S., Hoen, A. G., & Sankoh, O. (2013). The global distribution and burden of dengue. Nature, 496(7446), 504–507.
da Silveira, L. T. C., Tura, B., & Santos, M. (2019). Systematic review of dengue vaccine efficacy. BMC Infectious Diseases, 19, 1–8.
Godói, I. P., Lemos, L. L. P., De Araújo, V. E., Bonoto, B. C., Godman, B., & Guerra Junior, A. A. (2017). CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety. Journal of Comparative Effectiveness Research, 6(2), 165–180.
Harapan, H., Michie, A., Mudatsir, M., Sasmono, R. T., & Imrie, A. (2019). Epidemiology of dengue hemorrhagic fever in Indonesia: analysis of five decades data from the National Disease Surveillance. BMC Research Notes, 12, 1–6.
Rosa, B. R., da Cunha, A. J. L. A., & de Andrade Medronho, R. (2019). Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis. BMJ Open, 9(3), e019368.
World Health Organization. (2012). World Health Organization, and UNICEF. Handbook for clinical management of dengue.
World Health Organization. (2015). National guidelines for clinical management of dengue fever. World Health Organization.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Sonny Edbert, Hotimah Masdan Salim
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
